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CSF evidence of pericyte damage in
Alzheimer’s disease is associated with
markers of blood-brain barrier dysfunction
and disease pathology
J. S. Miners1* , P. G. Kehoe1, S. Love1, H. Zetterberg2,3,4,5† and K. Blennow2,3†
Abstract
Background: We aimed to assess the relationship between levels of a cerebrospinal fluid (CSF) marker of pericyte
damage, soluble platelet-derived growth factor receptor β (sPDGFRβ) and CSF markers of blood-brain barrier (BBB)
integrity (CSF albumin and CSF/serum albumin ratio) and disease pathology (reduced CSF Aβ42 and elevated CSF
total and phosphorylated tau) in Alzheimer’s disease (AD).
Methods: sPDGFRβ and albumin were measured by sandwich ELISA in ante-mortem CSF from 39 AD and 39 age-
matched controls that were grouped according to their biomarker profile (i.e. AD cases t-tau > 400 pg/mL, p-tau >
60 pg/mL and Aβ42 < 550 pg/mL). sPDGFRβ was also measured in matched serum and CSF samples (n = 23) in a
separate neurologically normal group for which the CSF/serum albumin ratio had been determined.
Results: CSF sPDGFRβ level was significantly increased in AD (p = 0.0038) and correlated positively with albumin
(r = 0.45, p = 0.007), total tau (r = 0.50, p = 0.0017) and phosphorylated tau (r = 0.41, p = 0.013) in AD but not in
controls. CSF sPDGFRβ did not correlate with Aβ42. Serum and CSF sPDGFRβ were positively correlated (r = 0.547,
p = 0.0085) in the independent neurologically normal CSF/serum matched samples.
Conclusions: We provide further evidence of an association between pericyte injury and BBB breakdown in AD
and novel evidence that a CSF marker of pericyte injury is related to the severity of AD pathology.
Keywords: Platelet-derived growth factor receptor β, PDGFRβ, Cerebrospinal fluid, CSF, CSF albumin, Alzheimer’s
disease
Background
Alzheimer’s disease (AD) and vascular dementia (VaD)
together account for most cases of dementia. Cerebral
hypoperfusion, neurovascular uncoupling and blood-
brain barrier (BBB) breakdown are defining features of
VaD, but there is now compelling evidence they are also
major contributors to cognitive decline and disease path-
ology in the early stages of AD (reviewed in [1, 2]). Peri-
cytes are a heterogeneous population of mural cells that
are highly enriched within the brain where they regu-
late blood flow and maintain vascular homeostasis.
Histological and biochemical assessment of post-mor-
tem brain tissue has revealed significant pericyte loss
in AD, associated with a reduction in the pericyte
marker platelet-derived growth factor receptor β
(PDGFRβ) [3, 4].
PDGFRβ is shed from human pericytes (but not vascu-
lar smooth muscle cells) when they are cultured under
hypoxic conditions (1% oxygen for 48 h) or exposed to
Aβ peptides [5]. Cell membrane shedding of PDGFRβ
was shown to be mediated by ADAM10 cleavage [6].
Elevation of the level of soluble PDGFRβ (sPDGFRβ) in
the CSF was associated with evidence on neuroimaging
of BBB leakiness within the hippocampus in normal
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ageing and in mild cognitive impairment [7]. Membrane
shedding of PDGFRβ from injured pericytes explains the
inverse relation between the loss of pericytes and reduc-
tion in PDGFRβ in the brain tissue and the elevation of
sPDGFRβ in the CSF in AD.
Nation et al. [6] reported increased CSF sPDGFRβ and
regional BBB leakiness in pre-clinical AD and reported
that CSF sPDGFRβ predicted cognitive decline inde-
pendently of CSF Aβ or tau level. The findings are in
keeping with data from PDGFRβ-deficient mice [8], indi-
cating that pericyte loss and BBB leakiness contribute to
cognitive decline and AD pathology. In the present
study, we sought to confirm the elevation of CSF
sPDGFRβ and association with BBB leakiness in AD and
to assess the relationship to markers of disease path-
ology, i.e. reduced Aβ42 and elevated total tau (t-tau)
and phosphorylated tau (p-tau).
Methods
Study cohort
CSF sPDGFRβ and albumin were measured in 39 AD
cases and 39 controls for which CSF t-tau, p-tau181P and
Aβ42 (Cat no 81583, 81551 and 81576 respectively) had
previously been determined using commercially available
sandwich enzyme-linked immunosorbent assays (ELI-
SAs) (INNOTEST, Fujirebio, Ghent, Belgium). All AD
patients had abnormal CSF levels of the core AD bio-
markers (t-tau > 400 pg/mL, p-tau > 60 pg/mL and Aβ42
< 550 pg/mL), while controls had normal levels (t-tau =
234.67 ± SD 11.42; p-tau 40.28 ± 1.58; Aβ42 834.18 ±
32.67). The cut-off values used in this study are in line
with current clinical practice and closely resemble those
outlined by Hansson et al. [9]. The mean ages were
76.21 years in the AD cases (SD 6.11) and 68.21 years in
the controls (SD 11.96). The proportions of males and
females were similar in the AD (25M, 14F) and control
(23M, 16F) cohorts. The demographic characteristics for
each cohort are summarised in Table 1. The present as-
says were performed on de-identified left-over aliquots
from clinical diagnostic CSF samples and followed the
Swedish Biobank law (Biobanks in Medical Care Act)
and procedures approved by the Ethical Committee at
University of Gothenburg. Cognitive data and APOE sta-
tus were not recorded, and matching serum samples
were not available for this cohort.
sPDGFRβ was, however, also measured in an inde-
pendent CSF and matched serum sample cohort from
neurologically normal controls (n = 23) spanning a larger
age range (23–84 years). The CSF/serum albumin ratio
had previously been determined by an immunoturbidi-
metric albumin method on Elecsys (Roche Diagnostics,
Penzberg, Germany). The demographics of this cohort
are presented in Table 2.
sPDGFRβ measurement in CSF and serum by sandwich
ELISA
CSF and serum sPDGFRβ levels were measured by sand-
wich ELISA (Invitrogen Cat no EHPDGFRB, Thermo
Fisher Scientific, Loughborough, UK). CSF samples
(100 μL undiluted) and serum (diluted 1 in 40 in propri-
etary dilution buffer supplied with the kit) were loaded.
Standards, samples and blanks were added in duplicate.
Absorbance was read at 450 nM in a FLUOstar OP-
TIMA plate reader (BMG labtech, Aylesbury, UK). Re-
producibility reported in the datasheet indicates an
inter-assay CV < 12% and intra-assay < 10%, with spike
recovery between 90 and 110% for serum, plasma and
cell culture media. PDGFRβ concentration in samples
was calculated by interpolation against the standard
curve for each case, derived from serial dilutions of
recombinant PDGFRβ (18,000–24 pg/mL). The mean
values from duplicate measurements are presented.
Albumin measurement in CSF by sandwich ELISA
CSF albumin level was measured by sandwich ELISA
(Cat no 108788) (Abcam, Cambridge, UK). CSF samples
were diluted 1 in 2000 in proprietary dilution buffer sup-
plied with the kit. Standards, samples and blanks were
added in duplicate. Absorbance was read at 450 nM in a
FLUOstar OPTIMA plate reader (BMG labtech, Ayles-
bury, UK). Albumin concentration in each sample was
interpolated from a standard curve derived from serial
dilution of recombinant human albumin (200–3.125 ng/
mL). The mean values are presented.
Statistical analysis
As the CSF sPDGFRβ and albumin levels were normally
distributed, unpaired two-tailed t tests or ANOVA with
Bonferroni post hoc correction was used for comparisons
between groups, and Pearson’s test was used to assess lin-
ear correlation. Data values outside the 99% confidence
interval of the linear regression line were considered to be
outliers and removed prior to statistical analysis. The ana-
lyses used SPSS version 16 (SPSS, Chicago) and GraphPad
Prism version 6 (GraphPad Software, La Jolla, CA). p
values < 0.05 were considered statistically significant.
Table 1 Summary demographics of the AD/control cohort
n Gender (M:F) Age (mean years ± SD) Aβ42 (mean ng/L ± SEM) p-tau (mean ng/L ± SEM) t-tau (mean ng/L ± SEM)
Control 39 23:16 68.2 ± 11.9 834.18 ± 32.67 40.28 ± 1.58 234.67 ± 11.42
AD 39 25:14 76.2 ± 6.11 435.18 ± 11.88 84.79 ± 3.21 725.69 ± 36.31
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Results
CSF sPDGFRβ levels were significantly higher in AD than
in controls (mean 426.7 pg/mL ± SD 20.9 in AD v 355.6
pg/mL ± 14.9 in controls) (p = 0.0038) (Fig. 1a). Mean CSF
albumin level was higher in AD than in controls, but the
difference did not reach statistical significance (150.1 μg/
mL ± 8.6 in AD v 135.6 μg/mL ± 6.9 in controls) (Fig. 1b).
CSF sPDGFRβ correlated with albumin in the AD co-
hort (r = 0.45, p = 0.007) but not in controls (r = 0.059,
p = 0.74) (Fig. 1c). Inspection revealed two obvious out-
liers that were both well outside the 99% confidence
interval of the linear regression line and were excluded
from analysis.
CSF sPDGFRβ correlated positively with t-tau in AD
(r = 0.50, p = 0.0017) but not in controls (r = 0.03, p =
0.83) (Fig. 1d), and with p-tau in AD (r = 0.41, p = 0.013)
but not in controls (r = 0.26, p = 0.10) (Fig. 1e). CSF
sPDGFRβ did not correlate with the CSF Aβ42 level in
the control cohort (r = 0.31, p = 0.054) or AD cohort
(r = − 0.04, p = 0.80) (Fig. 1f).
The control and AD groups did not differ significantly
according to age, and sPDGFRβ did not vary with age
within the controls (r = 0.10, p = 0.54) or AD (r = 0.29,
p = 0.077) groups (Additional file 1: Figure S1a). CSF
sPDGFRβ did not differ between gender in the controls
or AD cohort (Additional file 1: Figure S1b).
Table 2 Summary demographics of the independent neurologically normal CSF/serum matched cohort
n Gender (M:F) Age (mean years ± SD) Albumin ratio
CSF/serum cohort 23 12:11 58.13 ± 20.25 9.04 ± 1.19
Fig. 1 CSF soluble PDGFRβ level is increased in Alzheimer’s disease (AD) in relation to CSF markers of BBB leakiness (CSF albumin) and disease
pathology (elevated total tau (t-tau) and phosphorylated tau (p-tau)). a Dot plot showing significantly higher levels of CSF sPDGFRβ in AD
compared to controls (n = 39 per group) (p = 0.0038). b Dot plot showing CSF albumin level in the AD and controls (p = 0.18). c Scatterplots
showing positive correlation between CSF sPDGFRβ and CSF albumin in AD. d–f Scatterplots showing a positive correlation between CSF
sPDGFRβ and t-tau and p-tau but not with Aβ42 in AD. In a and b, the bars represent the mean ± SEM. In c–f, the best-fit linear regression line is
shown and 95% confidence intervals are superimposed. Each dot represents an individual sample. p < 0.05 was considered statistically significant
Miners et al. Alzheimer's Research & Therapy           (2019) 11:81 Page 3 of 6
We also measured sPDGFRβ in a separate non-AD co-
hort of matched CSF and serum sample from neuro-
logically heathy individuals. CSF and serum sPDGFRβ
level were positively correlated (r = 0.547, p = 0.0085)
(Fig. 2a). CSF sPDGFRβ did not correlate with the CSF/
serum albumin ratio (Fig. 2b).
Discussion
We have confirmed that CSF sPDGFRβ is increased in
AD, to an extent that correlates with CSF albumin level
(a marker of BBB leakiness) and with the neurodegener-
ation biomarkers CSF t-tau and p-tau. We have also
shown that the level of sPDGFRβ in CSF correlates with
that in serum in an independent cohort of matched
CSF/serum samples. Our findings support recent reports
of pericyte injury and BBB leakiness in AD, as demon-
strated in histological and biochemical studies of autopsy
tissue [4] and in biomarker and imaging studies in AD
patients [7]. Nation et al. recently reported that elevated
CSF sPDGFRβ was associated with cognitive decline in-
dependent of the levels of Aβ42 and tau in the early
stages of AD [6]. Here we have shown that in an AD co-
hort, elevated sPDGFRβ correlated with albumin, a CSF
marker of BBB leakiness, and with t-tau and p-tau levels
but not with Aβ42. Our novel finding of a correlation
between sPDGFRβ levels in the serum and CSF raises
the possibility of using serum sPDGFRβ measurements
to track the progression of pericyte injury and BBB
breakdown in AD.
Post-mortem studies have confirmed pericyte loss and
BBB leakiness in AD [3, 10]. Reduction in PDGFRβ is as-
sociated with biochemical evidence of cerebral hypoper-
fusion and BBB breakdown and with Aβ42 level in post-
mortem tissue [4]. The reduction in PDGFRβ is most
pronounced in brains from APOE ε4-positive AD
patients [3, 4]. PdgfrβF7/F7 mice, which have disrupted
PDGFRβ signalling, have a more pronounced vascular
phenotype associated with vascular loss and BBB leaki-
ness [11], and when Pdgdfβ+/− heterozygous mice were
crossed with Tg-APP mice, there was accelerated Aβ ac-
cumulation and clinical disease progression [8], support-
ing recent studies indicating that vascular dysfunction is
one of the earliest pathological features in pre-clinical
AD [12].
Compromised BBB integrity that can be demonstrated
in the hippocampus in normal ageing and is exacerbated
in MCI, as revealed by advanced dynamic contrast-en-
hanced MRI, is associated with elevated CSF sPDGFRβ
[7]. Nation et al. reported that elevated CSF sPDGFRβ in
mild cognitive impairment was related to BBB integrity
but was independent of CSF Aβ42 or tau [6]. Elevated
CSF sPDGFRβ likely reflects release of a soluble frag-
ment of pericyte PDGFRβ, due to its cleavage by
ADAM-10, as was shown in vitro in response to simu-
lated ischemia or Aβ peptide [5, 6]. Here we show that
elevation of CSF sPDGFRβ in AD is associated with BBB
leakiness but also correlates with established CSF
markers of AD progression, i.e. elevated CSF t-tau and
p-tau, although as in the Nation et al. study we did not
detect a direct relationship between CSF sPDGFRβ and
Aβ42. Larger cohort studies are needed to assess the
value of elevated sPDGFRβ in CSF, and perhaps even
serum, as a marker of progressive cognitive dysfunction
and the development of AD.
The mechanisms of pericyte injury in AD remain unclear,
but both Aβ and hypoperfusion are probably contributors.
Aβ peptides at supraphysiological concentrations were
shown to be toxic to human brain pericytes [13], dependent
on APOE genotype [14]. The toxic effects are probably re-
lated to the conformational assembly and species of Aβ
Fig. 2 Relationship between CSF and serum sPDGFRβ and the CSF/serum albumin ratio in an independent neurologically normal cohort (n = 23)
of matched CSF and serum. a Scatterplot showing a positive correlation between serum and CSF sPDGFRβ. b Scatterplot showing no relationship
between CSF sPDGFRβ and the CSF/serum albumin ratio. The best-fit linear regression line is shown and 95% confidence intervals are
superimposed. Each dot represents an individual sample. p < 0.05 was considered statistically significant
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[15]. In a bilateral carotid artery stenosis (BCAS) model that
mimics chronic cerebral hypoperfusion, pericyte loss and
BBB dysfunction in the corpus callosum preceded white
matter injury and cognitive decline [16]. The precise re-
gional distribution and timing of pericyte injury in AD, par-
ticularly in relation to other pathological manifestations of
the disease, has still to be determined.
Conclusions
This study has several limitations including the small
number of AD cases and controls and the paucity of
clinical details relating to the de-identified AD cases,
such as dementia severity, disease duration and APOE
genotype, that would be of interest for further analysis.
This is also an observational cross-sectional study and
does not provide clues as to the timing and regional
changes in pericyte loss in relation to onset and progres-
sion of disease. The extent of vascular burden within our
cohort is also unclear, and as in other clinical studies, it
is likely to include a spectrum of AD and mixed demen-
tia cases. Other variables that related to the collection of
the samples and might theoretically impact on the mea-
surements (e.g. time of day, needle type) were also not
available for analysis. Nonetheless, our data together
with recent studies suggest that markers of vascular dys-
function, including pericyte loss and BBB leakiness, are
related to cognitive impairment in MCI and disease
pathology in AD and can potentially be monitored by
analysis of CSF and possibly also serum. The inclusion
of vascular biomarkers as part of an AD research frame-
work, as suggested by Sweeney and colleagues [17],
would improve our understanding of AD pathophysi-
ology and may prove useful to identify those AD patients
for whom tailored therapies to reduce vascular burden
may offer a more effective treatment.
Additional file
Additional file 1: Figure S1 CSF-sPDGFRβ is not altered in relation to
age or gender. (a) Scatterplot showing no statistically significant
relationship between CSF-sPDGFRβ level and age in AD (red) and control
(green). The best-fit linear regression line and 95% confidence interval for
each group are superimposed. (b) Bar chart showing CSF-sPDGFRβ level
in control and AD group stratified for gender. No significant differences
were observed. Bars represent the mean ± SEM. (DOCX 209 kb)
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